vs
Side-by-side financial comparison of STRATA Skin Sciences, Inc. (SSKN) and Valens Semiconductor Ltd. (VLN). Click either name above to swap in a different company.
Valens Semiconductor Ltd. is the larger business by last-quarter revenue ($17.3M vs $9.3M, roughly 1.9× STRATA Skin Sciences, Inc.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -42.2%, a 42.9% gap on every dollar of revenue. On growth, Valens Semiconductor Ltd. posted the faster year-over-year revenue change (8.1% vs -3.0%). STRATA Skin Sciences, Inc. produced more free cash flow last quarter ($-551.0K vs $-4.9M).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
Valens Semiconductor (Valens) is an Israeli fabless manufacturing company providing semiconductors for the automotive and audio-video industries. Valens provides semiconductor products for the distribution of uncompressed ultra-high-definition (UHD) multimedia content and in-vehicle connectivity applications. The company is a member of the MIPI Alliance and developed the first-to-market chipset that is compliant with the MIPI A-PHY standard. Valens invented the technology behind the HDBaseT s...
SSKN vs VLN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.3M | $17.3M |
| Net Profit | $58.0K | $-7.3M |
| Gross Margin | 61.8% | 63.0% |
| Operating Margin | 5.3% | -46.4% |
| Net Margin | 0.6% | -42.2% |
| Revenue YoY | -3.0% | 8.1% |
| Net Profit YoY | 101.3% | 29.3% |
| EPS (diluted) | $0.14 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.3M | — | ||
| Q3 25 | $6.9M | $17.3M | ||
| Q2 25 | $7.7M | $17.1M | ||
| Q1 25 | $6.8M | $16.8M | ||
| Q4 24 | $9.6M | — | ||
| Q3 24 | $8.8M | $16.0M | ||
| Q2 24 | $8.4M | $13.6M | ||
| Q1 24 | $6.8M | — |
| Q4 25 | $58.0K | — | ||
| Q3 25 | $-1.6M | $-7.3M | ||
| Q2 25 | $-2.6M | $-7.2M | ||
| Q1 25 | $-2.1M | $-8.3M | ||
| Q4 24 | $-4.6M | — | ||
| Q3 24 | $-2.1M | $-10.4M | ||
| Q2 24 | $-91.0K | $-8.9M | ||
| Q1 24 | $-3.4M | — |
| Q4 25 | 61.8% | — | ||
| Q3 25 | 60.4% | 63.0% | ||
| Q2 25 | 56.2% | 63.5% | ||
| Q1 25 | 53.5% | 62.9% | ||
| Q4 24 | 61.4% | — | ||
| Q3 24 | 60.1% | 56.4% | ||
| Q2 24 | 59.0% | 61.4% | ||
| Q1 24 | 45.6% | — |
| Q4 25 | 5.3% | — | ||
| Q3 25 | -16.9% | -46.4% | ||
| Q2 25 | -30.1% | -43.3% | ||
| Q1 25 | -25.0% | -56.2% | ||
| Q4 24 | -44.7% | — | ||
| Q3 24 | -18.2% | -76.3% | ||
| Q2 24 | -5.7% | -69.2% | ||
| Q1 24 | -42.7% | — |
| Q4 25 | 0.6% | — | ||
| Q3 25 | -23.4% | -42.2% | ||
| Q2 25 | -33.6% | -42.1% | ||
| Q1 25 | -31.2% | -49.4% | ||
| Q4 24 | -47.6% | — | ||
| Q3 24 | -23.6% | -64.6% | ||
| Q2 24 | -1.1% | -65.2% | ||
| Q1 24 | -49.8% | — |
| Q4 25 | $0.14 | — | ||
| Q3 25 | $-0.36 | $-0.07 | ||
| Q2 25 | $-0.62 | $-0.07 | ||
| Q1 25 | $-0.51 | $-0.08 | ||
| Q4 24 | $-2.01 | — | ||
| Q3 24 | $-0.51 | $-0.10 | ||
| Q2 24 | $-0.03 | $-0.08 | ||
| Q1 24 | $-0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.9M | $93.5M |
| Total DebtLower is stronger | $15.3M | — |
| Stockholders' EquityBook value | $2.9M | $108.8M |
| Total Assets | $30.5M | $136.7M |
| Debt / EquityLower = less leverage | 5.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.9M | — | ||
| Q3 25 | $7.1M | $93.5M | ||
| Q2 25 | $6.0M | $102.7M | ||
| Q1 25 | $6.5M | $112.5M | ||
| Q4 24 | $7.3M | — | ||
| Q3 24 | $7.1M | $133.1M | ||
| Q2 24 | $5.5M | $105.9M | ||
| Q1 24 | $5.2M | — |
| Q4 25 | $15.3M | — | ||
| Q3 25 | $15.3M | — | ||
| Q2 25 | $15.0M | — | ||
| Q1 25 | $15.0M | — | ||
| Q4 24 | $15.0M | — | ||
| Q3 24 | $15.0M | — | ||
| Q2 24 | $15.0M | — | ||
| Q1 24 | $15.0M | — |
| Q4 25 | $2.9M | — | ||
| Q3 25 | $1.3M | $108.8M | ||
| Q2 25 | $532.0K | $116.5M | ||
| Q1 25 | $3.0M | $128.6M | ||
| Q4 24 | $5.0M | — | ||
| Q3 24 | $9.4M | $147.0M | ||
| Q2 24 | $9.5M | $153.5M | ||
| Q1 24 | $9.4M | — |
| Q4 25 | $30.5M | — | ||
| Q3 25 | $30.7M | $136.7M | ||
| Q2 25 | $29.5M | $144.8M | ||
| Q1 25 | $33.0M | $154.6M | ||
| Q4 24 | $34.9M | — | ||
| Q3 24 | $39.4M | $171.9M | ||
| Q2 24 | $38.8M | $175.8M | ||
| Q1 24 | $39.2M | — |
| Q4 25 | 5.28× | — | ||
| Q3 25 | 11.65× | — | ||
| Q2 25 | 28.20× | — | ||
| Q1 25 | 5.04× | — | ||
| Q4 24 | 3.02× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.58× | — | ||
| Q1 24 | 1.59× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-239.0K | $-4.7M |
| Free Cash FlowOCF − Capex | $-551.0K | $-4.9M |
| FCF MarginFCF / Revenue | -5.9% | -28.5% |
| Capex IntensityCapex / Revenue | 3.4% | 1.6% |
| Cash ConversionOCF / Net Profit | -4.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-4.4M | $-11.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-239.0K | — | ||
| Q3 25 | $-64.0K | $-4.7M | ||
| Q2 25 | $-1.9M | $-211.0K | ||
| Q1 25 | $-550.0K | $-7.6M | ||
| Q4 24 | $703.0K | — | ||
| Q3 24 | $-302.0K | $3.0M | ||
| Q2 24 | $591.0K | $-225.0K | ||
| Q1 24 | $-804.0K | — |
| Q4 25 | $-551.0K | — | ||
| Q3 25 | $-1.1M | $-4.9M | ||
| Q2 25 | $-2.0M | $-330.0K | ||
| Q1 25 | $-749.0K | $-8.0M | ||
| Q4 24 | $199.0K | — | ||
| Q3 24 | $-364.0K | $2.2M | ||
| Q2 24 | $246.0K | $-460.0K | ||
| Q1 24 | $-1.5M | — |
| Q4 25 | -5.9% | — | ||
| Q3 25 | -15.6% | -28.5% | ||
| Q2 25 | -26.1% | -1.9% | ||
| Q1 25 | -11.0% | -47.3% | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | -4.1% | 14.0% | ||
| Q2 24 | 2.9% | -3.4% | ||
| Q1 24 | -22.6% | — |
| Q4 25 | 3.4% | — | ||
| Q3 25 | 14.7% | 1.6% | ||
| Q2 25 | 0.8% | 0.7% | ||
| Q1 25 | 2.9% | 2.1% | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 0.7% | 4.5% | ||
| Q2 24 | 4.1% | 1.7% | ||
| Q1 24 | 10.7% | — |
| Q4 25 | -4.12× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
VLN
Segment breakdown not available.
